arsenic trioxide and sorafenib induce synthetic lethality of flt3-itd ...€¦ · 4 concentrations...
Post on 11-Jun-2020
2 Views
Preview:
TRANSCRIPT
1
Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute
myeloid leukemia cells
Rui Wang1#*, Ying Li2*, Ping Gong2, Janice Gabrilove1, Samuel Waxman1, and
Yongkui Jing 1, 2
1The Division of Hematology/Oncology, Department of Medicine, The Tisch Cancer Institute, Icahn
School of Medicine at Mount Sinai, New York, USA. 2Department of Pharmacology, Shenyang
Pharmaceutical University, Shenyang, China.
Running title: Targeting FLT3-ITD AML by a novel combination
Correspondence: Yongkui Jing Ph.D., Department of Pharmacology, Shenyang pharmaceutical
University, Liaoning 110016, China; E-mail: jingyongkui@syphu.edu.cn; Phone: 011-86-24-
23986975;
# Current address: Department of Pathology and Laboratory Medicine, Weill Cornell Medical
College-at Cornell University, New York, USA
*Both authors equally contributed as the first author.
There is no conflict of interest to disclose.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
2
Abstract:
Acute myeloid leukemia (AML) with Fms-related tyrosine kinase 3 internal tandem
duplication (FLT3-ITD) mutation is notoriously hard to treat. We identified two drugs that
together form an effective combination therapy against FLT3-ITD AML. One of the drugs,
Sorafenib, an inhibitor of FLT3-ITD and other kinase activity, produces an impressive but short-
lived remission in FLT3-ITD AML patients. The second, arsenic trioxide (ATO), at
therapeutically achievable concentrations, reduces the level of FLT3-ITD and Mcl-1 proteins, and
induces apoptosis in leukemic cell lines and in primary cells expressing FLT3-ITD. We linked
this relative sensitivity to ATO to low levels of reduced glutathione. While producing
proapoptotic effects, ATO treatment also has an unwanted effect whereby it causes the
accumulation of the phosphorylated (inactive) form of glycogen synthase kinase 3 (GSK-3) a
kinase necessary for apoptosis. When ATO is combined with Sorafenib, GSK-3β is activated,
Mcl-1 is further reduced, and proapoptotic proteins Bak and Bax are activated. Mice xenografted
with FLT3-ITD MOLM13 cell line treated with the Sorafenib/ATO combination have
significantly improved survival. This combination has potential to improve the therapeutic
outcome of FLT3-ITD targeted therapy of AML patients.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
3
Introduction:
Acute myeloid leukemia (AML) is heterogenous both in molecular abnormality and in response
to therapy. Patients with Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD)
mutation are the largest subgroup of AML patients with the poorest prognosis (1). FLT3-ITD, present
in ~ 25% of adult AML patients (2-3), is constitutively activated and, by itself, causes
myeloproliferative disorder, while in combination with other oncogenic pathways produces leukemia
(4-5). Several FLT3-ITD kinase inhibitors have been developed and tested in clinical trials (6-9).
They inhibit the activity of FLT3-ITD (10) and produce remissions in some AML patients; the latter
are short-lived ending in an inhibitor-resistant relapse (11-12). A few of the reasons for inhibitor
resistance have been discovered, including secondary mutations in the FLT3-ITD kinase domain (KD)
(13-14). Agents that will target FLT3-ITD with secondary mutations are being developed. Since
multiple mutations of FLT3-ITD have been identified in samples of therapy-resistant patients and cell
lines (14-16), finding inhibitors that will block each of these mutations would require a major effort.
To bypass this problem, we propose the use of agents aimed at elimination of the FLT3-ITD protein
itself, an approach used successfully to treat acute promyelocytic leukemia (APL) with its
pathognomonic fusion protein PML-RAR (17). However, the FLT3-ITD AML is a fatal disease
caused by multiple oncogenes and therefore its treatment will require a combination of drugs. Among
the clinically tested FLT3-ITD inhibitors, Sorafenib, a multi-kinase inhibitor approved for treatment of
several solid tumors (18), is one of the most effective inhibitors of FLT3-ITD AML cells (7, 9, 14, 19-
20). In off-label use, effectiveness of Sorafenib in FLT3-ITD AML patients has been reported (21-23).
Sorafenib improved clinical outcomes in FLT3-ITD AML patients when used prior to, and after bone
marrow transplant (24-26), but the effects were not long-lasting. However, due to its clinical use and
tolerable toxicity, Sorafenib appears to be an excellent candidate for developing combination therapy
for FLT3-ITD AML.
APL with t(15;17) coding PML-RAR fusion protein, a subtype of AML(M3), became a nearly
curable disease due to the development of all trans retinoic acid (ATRA) and arsenic trioxide (ATO),
both targeting PML-RAR fusion protein. Importantly, in about 40% of APL patients, in addition to
the presence of PML-RAR protein, mutant FLT3 are also detected (27). ATO alone or in
combination with ATRA is highly effective in producing long term remissions in APL patients which
also express FLT3-ITD (28-29). In 2 more recent studies the poor response of APL with FLT3-ITD to
ATRA and chemotherapy was improved by addition of ATO in front-line therapy (30-31). These
observations suggest to us that ATO, in addition to its known effect on PML-RAR protein
degradation (32), must also target FLT3-ITD. We previously showed (33) that Sorafenib, at
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
4
concentrations higher than 5 M in combination with ATO is a stronger inducer of apoptosis than each
agent alone and that the combination decreased Mcl-1 and GSH levels in non-FLT3-ITD AML cells.
Using FLT3-ITD AML cell lines and primary leukemia cells, we tested apoptosis induction by ATO
and its ability to eliminate FLT3-ITD protein. We also tested the combined effect of ATO with
Sorafenib in FLT3-ITD AML cells in vitro and in vivo. We found that FLT3-ITD AML cells contain
lower levels of GSH and that this property is linked to sensitivity to ATO-induced apoptosis. We also
showed that at therapeutic concentrations, ATO, is capable of degrading FLT3-ITD protein.
Sorafenib, at lower (nM) concentrations, when combined with ATO selectively augments apoptosis of
FLT3-ITD AML cells in vitro, significantly inhibits leukemia growth and prolongs survival of mice
xenografted with FLT3-ITD AML cells. We explored the possible mechanism responsible for the
enhancement of the combination treatment. Our work provides a new approach in which both the
FLT3-ITD protein and its kinase activity are targeted respectively for degradation and inhibition and
induction of synthetic lethality for FLT3-ITD AML therapy.
Materials and methods
Reagents. Arsenic trioxide for injection was obtained from the Pharmacy of Mount Sinai Hospital.
Sorafenib was obtained from LC Laboratories (Woburn, MA, USA). MG132 was purchased from
Sigma-Aldrich Inc (St. Louis, MO, USA). Bortezomib was acquired from Selleck Chemical (Houston,
TX, USA). Antibodies to Bcl-2, β-actin ERK1, FLT3, p-FLT3(Y591/589), HDAC6, Mcl-1 were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA); to PARP was from BD
Biosciences (San Diego, CA, USA ); to Ac-tubulin, Ac-lysine, Akt, Bim, p-ERK (Thr202/Tyr204),
GSK-3β, p-GSK-3β (Ser9), , p-rpS6 (Ser235/236), and rpS6 were from Cell Signaling Technology, Inc.
(Beverly, MA, USA). Anti-acetylated-HSP90(K243) antibody was obtained from Ruiying
Biotechnology(Suzhou, China) and HSP90 antibody was obtained from Enzo Life Sciences (San
Diego, CA).
Cell lines and treatments. MOLM13 cells were obtained from DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (Braunschweig Germany). THP-1 and MV-4-11 cells were
obtained from American Type Culture Collection (ATCC). These cell lines were cultured in RPMI
1640 medium supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L L-
glutamine, and 10% (v/v) heat-inactivated fetal bovine serum (FBS). 32D cells transfected with or
without FLT3-ITD were provided by Dr. Naoe (Nagoya University Graduate School of Medicine,
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
5
Japan received in 2012) (34). All cell lines were not authenticated by us once received in our
laboratory and mycoplasma was not tested. 32D cells were cultured in RPMI 1640 medium
supplemented with 1 ng/mL IL-3 and 32D/FLT3-ITD cells were cultured in RPMI 1640 medium
without supplemented with IL-3.
Detection of apoptosis and protein levels. Apoptotic cells were determined by the annexin V assay
according to the manufacturer’s instructions (annexin V–FITC Apoptosis Detection Kit (BD
Biosciences). Western blot analysis was used to measure protein levels. All these methods were done
as we previously reported (33, 35).
Analysis of Bak and Bax conformational changes. Cells treated with ATO plus Sorafenib were
harvested, washed in PBS, and suspended in lysis buffer {10 mM HEPES [pH 7.4], 150 mM NaCl, 1%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS]} containing protease
inhibitor cocktail. After 30-min incubation at 4ºC, the suspension was centrifuged for 15 min at
14,000 rpm. The obtained supernatant containing 500 µg protein was precleared by 20 µl protein A-
Agarose (Santa Cruz Biotechnology) and then subjected to immunoprecipitation with 3 µg of either
normal mouse IgG (Santa Cruz Biotechnology) or conformation-specific anti-Bak (clone Ab-1,
Calbiochem), anti-active Bax (clone 6A7, Sigma) at 4 ºC for 2 h with gentle rotation. After that, 30 µl
protein A-agarose beads were added and incubated overnight to pull down the protein-antibody
complexes. The bead pellets were then obtained by centrifuging and washed three times using lysis
buffer. The conformational changed Bak and Bax were determined by Western blot analysis using
anti-Bak and anti-Bax polyclonal antibodies (33).
Immunoprecipitation (IP) of FLT3 and HSP90. Cells treated and without treatment were harvested,
washed with PBS and lysed using ice-cold NP40 lysis buffer [50 mM Tris-HCl (pH7.5), 150 mM NaCl,
5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT] for 60 min on ice. Total
protein (400 µg) was first precleared with 20 µl protein A/G plus-agarose (Santa Cruz Biotechnology)
and then subjected to immunoprecipitation with 1-2 µg of either a normal IgG, a FLT3 antibody or a
HSP90 antibody (Enzo Life Sciences) at 4ºC for overnight. Then 20 µl of protein A/G plus-agarose
beads were added and incubated overnight to pull down protein-antibody complexes. The beads were
spun, washed four times with NP-40 lysis buffer, resuspended in 2 x SDS sample buffer (50 mM Tris-
HCl (pH 6.8), 2% SDS, 10% glycerol, 5% β-mercaptoethanol) and heated at 98ºC for 5 min for
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
6
analysis by SDS-polyacrylamide gel electrophoresis and Western blotting analysis using an anti-
HSP90 and an anti-Ac-lysine antibody, respectively.
Measurement of intracellular glutathione (GSH) content. The levels of intracellular GSH were
measured by a monochlorobimane (mBCl) fluorometric method in which mBCl was used as a
sensitive and specific probe to analyze GSH in intact cells (36). Briefly, cells were washed once,
resuspended in 1 mL PBS containing 100 μM mBCl, and maintained at 37ºC in the dark for 30 min
before analysis. The formation of the fluorescent adduct (GS-mBCl) was monitored with a Multi-mode
microplate reader (Spectra Max M5e; Molecular Devices, LLC, Sunnyvale, CA, USA) using excitation
and emission wavelengths of 395 and 482 nm, respectively. The GSH content was calculated as
nanomoles per 106 cells based on a GSH standard curve.
Isolation of patient-derived leukemic blood cells. Leukemic blood cells were obtained from three
peripheral blood samples of AML patients with FLT3-ITD (two samples with FLT3-ITD and NPM1
mutation, and one sample with FLT3-ITD and normal NPM1). The study was conducted in accordance
with International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS)
and that was approved by the Investigation Review Board of Icahn School of Medicine at Mount Sinai.
The written informed consent provided to the patients and signed forms were collect by our colleagues
before collection of the blood. Peripheral blood was collected in heparinized tubes and were subjected
to Ficoll-Hypaque density gradient separation. The leukemic blood cells were washed and resuspended
in RPMI-1640 with 20% FBS at 1 x 107 cells/ml and treated with ATO and/or Sorafenib, and then
subjected for apoptosis analysis after staining with annexin V–FITC and for Western blotting analysis .
In vivo treatment studies. The animal procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) of Icahn School of Medicine at Mount Sinai. Thirty NOD/SCID/IL-2Rg
(NSG) mice (age, 8 weeks) were injected with 2 × 106 log-phase MOLM13 cells subcutaneously in the
right flank (37). Mice with tumors of about 100 mm3 were randomized to six groups of five mice each
and were treated with Sorafenib (40 mg/kg) or ATO (2.5 or 5 mg/kg) or their combinations. A
Cremophor EL/ethanol/water solution (12.5% Cremophor EL/ 12.5% ethanol/ 75%water) containing
Sorafenib was prepared and was administered by oral gavage. ATO in PBS solution was administered
intraperitoneally. Mice were treated for 8 days. Tumors were measured every two days. The tumors in
each mice were dissected at day 9 and weighted. In second experiment, twenty NSG mice (age, 8
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
7
weeks) were injected with 5 × 106 log-phase MOLM13 cells via the lateral tail vein. Five days after
leukemic cell injection, the mice were divided randomly into 4 groups and treated with Sorafenib (20
mg/kg, p.o.), ATO (5 mg/kg, i.p.) alone or their combination daily for five continuous days a week and
kept until the mice deceased. Control mice received the vehicle through the same route and on the
same schedule. Survival times of each group were compared with Kaplan–Meier survival analysis and
the increase of life span (ILS) was calculated as (treated group-control group)/control group x 100%
Statistical analysis
Data were analyzed for statistical significance using student’s t test (Microsoft Excel, Microsoft Corp.,
Redmond, WA, USA). A p-value of <0.05 was considered statistically significant.
Results:
FLT3-ITD AML cell lines contain lower levels of GSH and are sensitive to ATO-induced
apoptosis. Previously we have found that APL cells contained lower levels of GSH and were
sensitive to ATO-induced apoptosis and PML-RAR degradation at therapeutic concentrations (1-2
M) (38). We and other groups also found that other malignant cells with lower GSH levels were
sensitive to ATO-induced apoptosis (39-41). We now compared the GSH content of two FLT3-ITD
expressing cell lines (MV4-11 and MOLM13) to that of a cell line expressing wFLT3 (THP-1), and
found that GSH levels in MV4-11 and in MOLM13 cells were, respectively, 80% and 50% lower
than that in THP-1 cells (Fig. 1A). Apoptosis was induced in a dose-dependent manner by 1-4 M of
ATO in MV4-11 and MOLM13 cells, but was only slightly induced in THP-1 cells (Fig. 1B). To test
whether FLT3-ITD was responsible for the reduction in GSH levels and for the subsequent sensitivity
to ATO we compared parental 32D cells to those transfected with FLT3-ITD (34) and found that the
latter had decreased GSH levels (Fig. 1C). 32D cells expressing FLT3-ITD were more sensitive to
ATO-induced apoptosis than the parental cells at every concentration tested (Fig. 1D). FLT3-ITD is
constitutively active due to autophosphorylation. To test if activation of wtFLT3 causes GSH
reduction and increases sensitivity to ATO, we treated THP-1 cells expressing wtFLT3 with FLT3-
ligand. FLT3-ligand at a concentration of 100 ng/ml decreased the levels of GSH by about 27% (Sup.
Fig. 1A), but did not enhance ATO-induced apoptosis in THP-1 cells (Sup. Fig. 1B). These data
suggest that FLT3-ITD might be the factor which not only lowers GSH levels but also renders those
cells more sensitive to ATO-induced apoptosis.
ATO induces degradation of FLT3-ITD. We found that treatment with ATO (at 1 and 2 μM)
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
8
reduced the levels of FLT3-ITD and, to a lesser extent, the phosphorylated FLT3-ITD protein in
MOLM13 cells (Fig. 2A), but had only a minimal effect on wtFLT3 in THP-1 cells (Fig. 2C). In
32D cells transfected with FLT3-ITD, ATO treatment reduced both total and auto-phosphorylated
FLT3-ITD (Fig. 2B). Since FLT3-ITD AML cells contain lower levels of GSH, we tested if depleting
GSH enhances ATO-induced degradation of wtFLT3 and apoptosis in THP-1 cells. We pretreated
THP-1 cells with buthionine sulfoximine (BSO), which inhibited GSH synthesis and depleted GSH
in most cancer cells (40), and found that in BSO pre-treated cells 1 μM of ATO was indeed able to
decrease the levels of the wtFLT3 protein and to induce apoptosis based on PARP cleavage (Fig. 2D).
These data support the notion that activated FLT3-ITD sensitizes cells to ATO, at least in part,
through lowering GSH levels. It has been shown that FLT3-ITD is a client protein of HSP90 and that
the levels of FLT3-ITD protein are decreased in cells treated with HSP90 inhibitors (42-43). The
affinity of HSP90 for client proteins is regulated by acetylation through HDAC6 (44). ATO has been
reported to inhibit HDAC6 activity in myeloma cells (45). We found that in MOLM13 cells treated
with ATO HDAC6 activity was decreased, as judged by the increase in its substrate (acetylated α-
tubulin), and this was associated with the decrease in the levels of HDAC6 protein (Fig.2A). The
FLT3-ITD bound HSP90 was decreased and the acetylated HSP90 level was increased in MOLM13
cells treated with ATO at 1 and 2 M as determined by immunoprecipitation assay (Fig. 2E). It has
been reported that after inhibition of HSP90, FLT3-ITD undergoes proteasomal degradation (46) but
also it reported that the proteasome inhibitors induce FLT3-ITD degradation through autophagy-
mediated pathway (47). We found that ATO-induced FLT3-ITD degradation was not blocked by
proteasome inhibitors Boretzomib and MG132 but that treatment with either one of these inhibitors
induced the microtubule-associated protein 1A/1B-light chain 3 (LC3) cleavage, a marker of
autophagy, suggesting that FLT3-ITD degradation is linked to autophagy after treatments with both
Boretzomib and MG132 (Fig. 2F). Our data suggest that ATO treatment interrupts the axis of
HDAC6/HSP90/FLT3-ITD leading to FLT3-ITD degradation.
ATO and Sorafenib regulate the levels of phosphorylated-GSK3 and BimEL differently in
FLT3-ITD AML cells. Previously we found (33) that the mechanism through which ATO induced
apoptosis in APL-NB4 cells involved repression of Mcl-1 protein by GSK3β activation (inhibition of
its phosphorylation). We observed a similar reduction in Mcl-1 protein level in MOLM13 cells
treated with ATO, but rather than being decreased, the phosphorylated GSK3 levels were elevated
(Fig. 3A). However, we observed that ATO treatment of MOLM13 cells inhibited ERK and rpS6
phosphorylation and decreased Akt and BH3-only BimEL protein (Fig. 3A). These data suggest that
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
9
an Akt-independent inactivation (phosphorylation) of GSK3 occurs in ATO-treated FLT3-ITD AML
cells that may attenuate ATO-induced apoptosis. Sorafenib is one of FLT3-ITD inhibitors used off-
label in AML patients. At lower concentrations of Sorafenib FLT3-ITD AML cells are more
responsive to apoptosis induction than other AML cells (48). We tested the effect of Sorafenib on
Mcl-1, phosphorylated GSK3 and Bim levels. Sorafenib at 50 nM was sufficient to induce
apoptosis and to decrease Mcl-1 protein level and FLT3-ITD phosphorylation. It also reduced p-
GSK3 levels and increased BimEL (Fig. 3B). This change coincided with PARP cleavage (Fig. 3B).
Sorafenib is a multi-kinase inhibitor which also inhibits the FLT3-ITD kinase. To test if the reduction
in GSK3 phosphorylation is through inhibition of FLT3-ITD, we tested the levels of p-FLT3-ITD
and p-GSK3 in MOLM13 cells treated with AC220, a specific inhibitor of FLT3-ITD (10). Like
Sorafenib (Fig. 3B), AC220 inhibited the phosphorylation of FLT3-ITD and GSK3 and induced
apoptosis in MOLM13 cells (Sup. Fig. 2A). These data suggest that, at low concentrations, Sorafenib
leads to GSK3 activation (de-phosphorylation) through inhibition of FLT3-ITD activity in FLT3-
ITD AML cells.
Combination of ATO and Sorafenib enhances apoptosis in FLT3-ITD AML cell lines and
primary AML cells. We treated MOLM13 cells with a combination of 0.5-1 μM of ATO and 25-100
nM of Sorafenib and found that these combinations significantly enhanced apoptosis (Fig. 4A). The
combination indexes were analyzed using Compusyn software showing CIs of less than 1, indicating
synergy (Fig. 4B). In comparison to the effect of the individual drugs, the combination of 1 μM of
ATO with 25 nM of Sorafenib increased PARP cleavage, further reduced Mcl-1 level (Fig. 4C).
Sorafenib treatment alone shifts the balance of FLT3-ITD toward the heavier, glycosylated mature
form, known to localize to the plasma membrane (49). Both forms were decreased by ATO treatment
(Fig. 4C). Although ATO alone increased the levels of p-GSK3, Sorafenib in combination with
ATO decreased the levels of p-GSK3 (Fig. 4C). The finding that ATO together with AC220 also
increases apoptosis in MOLM13 cells, while reducing levels of p-GSK3 (Sup. Fig. 2B) suggests
that GSK3 is activated in the combination treatments and contributed to the enhanced apoptosis
induction. Mcl-1 is an antiapoptotic protein that blocks Bak activation and that Bim is a proapoptotic
protein that activates Bax (50). Immunoprecipitation analysis revealed that Sorafenib was more
effective than ATO in activating both Bak and Bax and that enhanced Bak activation, not Bax
activation, was observed in the combination treatment (Fig . 4D). To test the role of GSK3 in this
combination treatment, GSK3 inhibitor SB216763 was used. SB216763 inhibited both Bax and
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
10
Bak activation in Sorafenib/ATO treated MOLM13 cells with more profoundly on Bax activation
(Fig. 4E) and reduced apoptotic cells from 63% to 28% (Sup. Fig. 3). Previously we found that
Sorafenib enhanced ATO-induced apoptosis and GSK3 activation by depleting GSH in HL-60 cells
(33). This required high concentrations of Sorafenib. We measured the levels of GSH in either
Sorafenib or AC220 treated cells, and found that both decreased GSH levels at concentrations which
inhibited FLT3-ITD phosphorylation (Sup. Fig. 4). However, Sorafenib at 25 nM and AC220 at 2
nM, the concentrations sufficient to enhance ATO-induced apoptosis, did not significantly decrease
the levels of GSH (Sup. Fig. 4). These data suggest that FLT3-ITD activity regulates GSH levels, but
that the apoptosis induced by the two drug combination might not involve GSH depletion. We
propose that the enhanced apoptosis induction by this combination results from that 1) ATO and
sorafenib inhibit FLT3-ITD through different mechanisms which release repression on GSK3; 2)
ATO treatment causes a feedback inactivation of GSK3 which is overcome by Sorafenib; 3) GSK3
activation plays an important role in the activation of Bax/Bak and apoptosis induction (Fig. 4F).
To examine whether apoptosis is enhanced by the combination therapy in primary leukemic
cells, three blood samples from patients with FLT3-ITD leukemia were used to test for the levels of
FLT3-ITD and apoptosis after treatment with ATO alone and in combination with Sorafenib.
Concentration higher than 2.5 M of Sorafenib alone was required to induce apoptosis in these cells.
The sensitivity to ATO was equal to that of MOLM13 (Fig. 5A); at 1 M and 2 M ATO decreased
the FLT3-ITD, Mcl-1 and Akt levels (Fig. 5B). Importantly, addition of ATO augmented Sorafenib-
induced apoptosis (Fig. 5A). These data indicate that ATO is able to decrease FLT3-ITD and Mcl-1
proteins in primary cells and enhances Sorafenib-induced apoptosis at a clinically achievable
concentration.
ATO enhances Sorafenib effect in NSG mice xenografted with FLT3-ITD MOLM13 cells. We
tested the effect of treatment with Sorafenib alone (40 mg/kg); ATO alone (2.5 mg/kg); ATO alone (5
mg/kg); and the combinations of the two (ATO 2.5 mg/kg and Sorafenib 40 mg/kg) and (ATO 5
mg/kg and Sorafenib 40 mg/kg) on growth of MOLM13 cells inoculated s.c. into NSG mice.
Treatment was initiated at day 5 after cell inoculation and lasted for 8 days. Sorafenib (p.o.) alone or
ATO (i.p.) alone reduced tumor size by ~50% (Fig. 6A). The combination of 40 mg/kg of Sorafenib
with 5 mg/kg of ATO produced a profoundly (~90%) and significantly reduced tumor size without
obvious toxic effect as determined by the maintenance of body weight (Fig. 6A and Sup. Fig. 5). We
inoculated MOLM13 cells i.v. through tail vein and treated the mice with Sorafenib (20 mg/kg, p.o.)
alone, ATO (5 mg/kg, i.p.) alone or with the combination. Treatment was initiated at day 5 after cell
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
11
inoculation and lasted until mice were deceased. These mice survived for an average of 17 days
without treatment, ATO alone had a minor effect, Sorafenib prolonged significantly the survival of
the leukemia mice (an average of 34 days) while the combination extended the survival to an average
of 47 days (Fig. 6B, 6C).
Discussion
FLT3-ITD AML remains a very serious, incurable illness with an urgent need for new effective
treatments. The current approaches to inhibit FLT3-ITD kinase activity with several inhibitors,
although clinically effective, produce only transient responses due to the development of resistance
(51). We explored the possibility of targeting FLT3-ITD protein for degradation as a therapy. We
found that at clinically achievable concentrations of 1-2 M, ATO treatment caused degradation of
FLT3-ITD protein and induced apoptosis associated with the down-regulation of Mcl-1 in cell lines
and primary cells with FLT3-ITD (Fig. 3A, 5B). Previously we found that APL cells were relatively
sensitive to ATO-induced apoptosis due to lower levels of GSH than that in other types of AML cells
(38). We found that the sensitivity to ATO in FLT3-ITD cells was also partially defined by the lower
level of GSH (Fig. 1A, 1B). Forced expression of FLT3-ITD reduced the levels of GSH and sensitized
32D cells to ATO-induced apoptosis (Fig. 1C, 1D). We found that, by decreasing the level of HDAC6
protein, ATO inhibited HDAC6 activity (Fig. 2A), led to increased acetylation of HSP90, and
dissociated from FLT3-ITD (Fig. 2E). This is a new mechanism of FLT3-ITD degradation by ATO in
which by interrupting the interaction between FLT3-ITD and HSP90. The sensitivity of FLT3-ITD to
ATO-induced degradation depends on the lower levels of GSH.
Mcl-1 is the most critical anti-apoptotic protein for acute myeloid leukemia survival (52).
FLT3-ITD has been shown to up-regulate Mcl-1 (53) while decreasing the pro-apoptotic BH3-only
protein Bim (54). Bim is crucial for apoptosis induction because of its ability to bind all anti-apoptotic
Bcl-2 family members (55) and to directly activate Bax (56). Both Mcl-1 and Bim are being
considered as targets in leukemia therapy (57-58). Both Mcl-1 and Bim are regulated by GSK3. Bim
is stabilized while Mcl-1 is destabilized by phosphorylation with GSK3. The activity of GSK3 is
also controlled by phosphorylation; the phosphorylated GSK3 is the inactive form. We found that in
ATO treated MOLM13 cells phosphorylated GSK-3 levels were elevated while Bim levels were
reduced even with decreased levels of Mcl-1 (Fig. 3A). These data suggest that ATO reduces Mcl-1
through a GSK3β-independent mechanism and that GSK3 inactivation may play a negative role in
ATO induced apoptosis probably due to destabilization of Bim, a scenario that needs to be overcome.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
12
Among the inhibitors of FLT3-ITD kinase, Sorafenib was reported to inhibit Mcl-1 and upregulate
Bim in AML cells (48). We found that in FLT3-ITD AML cells Sorafenib, at a low concentration (50
nM), decreased the levels of Mcl-1 and phosphorylated GSK3 while increasing the levels of Bim (Fig.
3B). When combined with ATO, Sorafenib was able to block the ATO-induced GSK3 phosphorylation,
further reduced Mcl-1 level and increased Bim level (Fig. 4C), leading to activation of both Bak and
Bax (Fig, 4D). We found that activation of GSK3 (de-phosphorylation) by Sorefenib was associated
with inhibition of FLT3-ITD activity (Fig. 3B). Inhibition of FLT3-ITD by a specific inhibitor AC220
(Supp. Fig 2A), also enhances ATO-induced apoptosis in MOLM13 cells (Sup. Fig. 2B). GSK3
inhibitor SB216763 significantly attenuated ATO/Sorafenib-induced apoptosis and Bax/Bak activation
(Fig. 4E and Sup. Fig. 3), suggesting that a GSK3 to Bax/Bak activation cascade contributes to the
apoptosis induction by these drugs combination (Fig. 4F). ATO in combination with Sorafenib at lower
concentrations selectively induced apoptosis only in FLT3-ITD AML cells, but not in wtFLT3 THP-1
cells (Fig. 2B), suggesting that ATO and Sorafenib combination would most likely have limited toxicity
in normal tissues. However, the effect of this combination on wtFLT3 patients samples and normal
CD34+ cells should be tested and compared in the future studies. The relative selectivity of this
combination depends on the presence of FLT3-ITD and the lower levels of intracellular GSH, which is
regulated by FLT3-ITD (Fig. 1). Therefore, the presence of FLT3-ITD not only provides a target for
Sorafenib but also creates a sensitive condition for effective ATO treatment. The combination of ATO
and Sorafenib could be translated into a successful combination therapy for FLT3-ITD AML patients.
Acknowledgments:
This work was partly supported by The Samuel Waxman Cancer Research Foundation to Y. Jing. We
thank Dr. Liliana Ossowski (Icahn School of Medicine at Mount Sinai) for editing of this manuscript.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
13
References cited:
1. Grimwade D. The changing paradigm of prognostic factors in acute myeloid leukaemia. Best
Pract Res Clin Haematol. 2012;25:419-25.
2. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid
leukemia. Oncologist. 2007;12:341-55.
3. Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic.
Hematology Am Soc Hematol Educ Program. 2010;2010:47-55.
4. Chan PM. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a
working model. Protein Cell. 2011;2:108-15.
5. Testa U, Pelosi E. The Impact of FLT3 Mutations on the Development of Acute Myeloid
Leukemias. Leuk Res Treatment. 2013;2013:275760.
6. Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2015;19:37-54.
7. Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid
leukemia: quizartinib and beyond. Ther Adv Hematol. 2014;5:65-77.
8. Grunwald MR, Levis MJ. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy
and mechanisms of resistance. Int J Hematol. 2013;97:683-94.
9. Kayser S, Levis MJ. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical
implications and limitations. Leuk Lymphoma. 2014;55:243-55.
10. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, et al. AC220 is
a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia
(AML). Blood. 2009;114:2984-92.
11. Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid
leukemia. Leukemia. 2012;26:2176-85.
12. Levis M. FLT3/ITD AML and the law of unintended consequences. Blood. 2011;117:6987-90.
13. Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, et al. Mutations of FLT3/ITD
confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013;27:48-55.
14. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, et al. Validation of ITD
mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature.
2012;485:260-3.
15. Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, et al. Emergence
of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib
and sunitinib in FLT3-ITD-positive acute myeloid leukemia. Clin Cancer Res. 2013;19:5758-68.
16. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, et al. Activity of ponatinib
against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood.
2013;121:3165-71.
17. Lallemand-Breitenbach V, Zhu J, Chen Z, de The H. Curing APL through PML/RARA
degradation by As2O3. Trends Mol Med. 2012;18:36-42.
18. Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, et al. The sorafenib plus
nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells
irrespectively of FLT3 and p53 status. Haematologica. 2012;97:1722-30.
19. Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert
Opin Investig Drugs. 2013;22:1659-69.
20. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, et al. Sorafenib treatment of FLT3-
ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent
nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119:5133-43.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
14
21. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate
use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and
after allogeneic stem cell transplantation. Blood. 2009;113:6567-71.
22. Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A, et al. Sorafenib (Nexavar)
induces molecular remission and regression of extramedullary disease in a patient with FLT3-
ITD+ acute myeloid leukemia. Leuk Res. 2009;33:348-50.
23. Lee SH, Paietta E, Racevskis J, Wiernik PH. Complete resolution of leukemia cutis with
sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol.
2009;84:701-2.
24. Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, et al. Phase I trial of maintenance
sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3
internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant.
2014;20:2042-8.
25. Liegel J, Courville E, Sachs Z, Ustun C. Use of sorafenib for post-transplant relapse in
FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
Haematologica. 2014;99:e222-4.
26. Sammons SL, Pratz KW, Smith BD, Karp JE, Emadi A. Sorafenib is tolerable and improves
clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell
transplant and after relapse post-transplant. Am J Hematol. 2014;89:936-8.
27. Beitinjaneh A, Jang S, Roukoz H, Majhail NS. Prognostic significance of FLT3 internal tandem
duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic
review. Leuk Res. 2010;34:831-6.
28. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3
mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed
acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Haematologica. 2007;92:994-5.
29. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans
retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Proc Natl Acad Sci U S A. 2009;106:3342-7.
30. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic
acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia
(APML4). Blood. 2012;120:1570-80; quiz 752.
31. Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, et al. Arsenic
trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance
of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55:1523-32.
32. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood.
2008;111:2505-15.
33. Wang R, Xia L, Gabrilove J, Waxman S, Jing Y. Downregulation of Mcl-1 through GSK-3beta
activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Leukemia. 2013;27:315-24.
34. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with
internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21:2555-63.
35. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, et al. Combined effect of all-trans
retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Blood. 2001;97:264-9.
36. Fernandez-Checa JC, Kaplowitz N. The use of monochlorobimane to determine hepatic GSH
levels and synthesis. Anal Biochem. 1990;190:212-9.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
15
37. Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, et al. Selective FLT3
inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a
model for emerging clinical resistance patterns. Leukemia. 2012;26:1462-70.
38. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth
inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Blood. 1999;93:268-77.
39. Bhalla S, Gordon LI, David K, Prachand S, Singh AT, Yang S, et al. Glutathione depletion
enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-
independent mechanisms. Br J Haematol. 2010;150:365-9.
40. Chen D, Chan R, Waxman S, Jing Y. Buthionine sulfoximine enhancement of arsenic trioxide-
induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-
terminal kinase and up-regulation of death receptors. Cancer Res. 2006;66:11416-23.
41. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, et al. Apoptosis and growth inhibition in
malignant lymphocytes after treatment with arsenic trioxide at clinically achievable
concentrations. J Natl Cancer Inst. 1999;91:772-8.
42. Yu C, Kancha RK, Duyster J. Targeting oncoprotein stability overcomes drug resistance caused
by FLT3 kinase domain mutations. PLoS One. 2014;9:e97116.
43. Kancha RK, Bartosch N, Duyster J. Analysis of conformational determinants underlying HSP90-
kinase interaction. PLoS One. 2013;8:e68394.
44. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone
deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel
basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005;280:26729-
34.
45. Qu X, Du J, Zhang C, Fu W, Xi H, Zou J, et al. Arsenic trioxide exerts antimyeloma effects by
inhibiting activity in the cytoplasmic substrates of histone deacetylase 6. PLoS One.
2012;7:e32215.
46. Buchwald M, Pietschmann K, Muller JP, Bohmer FD, Heinzel T, Kramer OH. Ubiquitin
conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation.
Leukemia. 2010;24:1412-21.
47. Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, et al. Proteasome inhibitors induce
FLT3-ITD degradation through autophagy in AML cells. Blood. 2016;127:882-92.
48. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, et al. Sorafenib
induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
Leukemia. 2008;22:808-18.
49. Schmidt-Arras DE, Bohmer A, Markova B, Choudhary C, Serve H, Bohmer FD. Tyrosine
phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol. 2005;25:3690-
703.
50. Czabotar PE, Colman PM, Huang DC. Bax activation by Bim? Cell Death Differ. 2009;16:1187-
91.
51. Larrosa-Garcia M, Baer MR. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and
Future Directions. Mol Cancer Ther. 2017;16:991-1001.
52. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is
essential for the development and sustained growth of acute myeloid leukemia. Genes Dev.
2012;26:120-5.
53. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, et al. FLT3-
ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-
ITD-specific STAT5 activation. Blood. 2009;114:5034-43.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
16
54. Scheijen B, Ngo HT, Kang H, Griffin JD. FLT3 receptors with internal tandem duplications
promote cell viability and proliferation by signaling through Foxo proteins. Oncogene.
2004;23:3338-49.
55. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin
Cell Biol. 2005;17:617-25.
56. Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci.
2003;116:4053-6.
57. Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk
Res Rep. 2013;2:12-4.
58. Harada H, Grant S. Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev
Eukaryot Gene Expr. 2012;22:117-29.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
17
Figure legends:
Figure 1. FLT3-ITD AML cells contain lower levels of GSH and are more sensitive to ATO-
induced apoptosis than wild type FLT3 AML cells. A, Comparison of intracellular GSH levels of
MV4-11 (FLT3-ITD), MOLM13 (FLT3-ITD) and THP-1 (wild type FLT3) cells. ** p < 0.01,
comparing to THP-1 cells. B, Apoptosis induced by ATO in MOLM13, MV4-11 and THP-1 cells.
Cells treated with ATO for 24 h were examined for apoptosis using Annexin V staining and FACS. C,
Intracellular GSH levels of 32D cells (parental) or transfected with FLT3-ITD. D, ATO-induced
apoptosis in 32D cells (parental) or transfected with FLT3-ITD. Cells treated with ATO for 24 h were
stained with Annexin V and analyzed by FACS for apoptosis. ** p< 0.01 (32D/FLT3-ITD compared to
parental 32D cells).
Figure 2. ATO induced degradation of FLT3-ITD, but not wtFLT3, associated with lower levels
of GSH and inhibition of HDAC6. A, MOLM13 cells were treated with ATO at the indicated
concentrations for 24 h and the protein levels of FLT3-ITD, HDAC6, Ac--tubulin were determined by
Western blot analysis. B, 32D/FLT3-ITD cells were treated with ATO for 24 h and FLT3-ITD and
phosphorylated FLT3-ITD were measured. C, THP-1 cells were treated with ATO at the indicated
concentrations for 24 h and the levels of FLT3 were determined. D, THP-1 cells were pretreated with or
without 200 μM of BSO for 4 h and then with 1 μM of ATO for 24 h. The levels of FLT3 and cleaved
PARP were determined. E, The interaction of HSP90 with FLT3-ITD (left panel) and acetylated HSP90
(right panel) were determined in MOLM13 cells treated with ATO for 24 h using immunoprecipitation
and Western blot analysis. F, MOLM13 cells were pretreated with 1 M of ATO for 16 h then in
combination with 50 nM of bortezomib (Bor) or 5M of MG132 for 8 h and the levels of FLT3-ITD
and autophagy marker LC3 were determined.
Figure 3. Different effects of ATO and Sorafenib (Sor) on the levels of Mcl-1, BimEL and
phosphorylated GSK3β in MOLM13 cells. MOML13 cells were treated with ATO (A) or Sorafenib
(B) at the indicated concentrations for 24 h. The protein levels of the antiapoptotic proteins, ERK and
Akt and their downstream products were determined using Western blot analysis.
Figure 4. Synergistic apoptosis induction by ATO in combination with Sorafenib in MOLM13
cells linked to activation of Bak, Bax and GSK3. A, Apoptotic cells in MOLM13 cells treated for
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
18
24 h with Sorafenib (Sor) alone at the indicated concentrations or combined with 0.5M or 1μM of
ATO. B, The median dose effect was analyzed using CompouSyn software to determine synergy. CI
values of less than 1.0 (horizontal line) corresponds to a synergistic interaction. Fa on the x-axis denotes
the fraction affected. C, Western blot analyses of FLT3-ITD, Mcl-1 and Bim, phosphorylated GSK3
and PARP cleavage in MOLM13 cells treated for 24h with Sorafenib, ATO or their combination. D,
Activated Bak and Bax in MOLM13 cells treated with ATO, Sorafenib, and their combination for 24 h
were detected by immunoprecipitation and Western blot analysis. E, Effect of GSK3 inhibitor
SB216763 on the levels of activated Bax and Bak in MOLM13 cells treated with ATO/Sorafenib for
24 h. MOLM13 cells were pretreated with SB216763 for 4 h and then with ATO/Sorafenib at the
indicated concentrations for 24 h. The activated Bak and Bax were determined by immunoprecipation
and Western blot analysis. F, The potential working model of Sorafenib in combination with ATO to
enhance apoptosis induction in FLT3-ITD AML cells.
Figure 5. Sorafenib/ATO combination enhances apoptosis in primary FLT3-ITD AML cells. A,
Primary FLT3-ITD leukemia cells from 3-AML patients were treated for 24 h with 5 µM of Sorafenib, 1
or 2 µM of ATO or their combination. Apoptotic cells were detected with Annexin V-FITC using flow
cytometry. ** p<0.01 (combination treated group compared to single agent treatment). B, Western
blot analysis of FLT3-ITD, Mcl-1, Akt, and GAPDH in samples 1 and 2.
Figure 6. Sorafenib/ATO combination significantly inhibit growth of MOLM13 cells in NSG mice.
A, Tumor weights of MOLM13 cells grown in mice inoculated s.c. and treated daily for 8 days with
PBS, Sorafenib 40 mg/kg, ATO 2.5 mg/kg and 5 mg/kg as well as the combinations. * p<0.05;
**p<0.01; ***p<0.001 compared to control group. ##, p<0.01 compared to single agent treatment. B &
C, Survival of mice inoculated with MOLM13 cells through the tail vein and treated with Sorafenib (20
mg/kg), ATO (5 mg/kg) and the combination and kept until the mice decreased. Kaplan-Meyer survival
plot (B) and the average survival times of each group and an increase in life span (ILS) were calculated
(C). ##p<0.01 compared to Control group; *p<0.05 compared to Sorafenib alone group.
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
0
5
10
15
20
25
30
35
40
45
50
0 1 2
An
nexin
V-p
osit
ive c
ells (
%)
ATO Concetration (μM)
32D
32D/FLT3-ITD
0
5
10
15
20
25
30
35
THP-1 MV-4-11 MOLM13
GS
H c
on
ten
t
(nm
ol/
10
6 c
ells)
**
**
B A
C D
**
**
Fig. 1
0
10
20
30
40
50
60
70
80
90
0 1 2 4
An
nexin
V-p
osit
ive c
ells
(%)
ATO Concentration (μM)
THP-1
MV-4-11
MOLM13
**
0
5
10
15
20
25
32D 32D/FLT3-ITD
GS
H C
on
ten
ts
(nm
ol/
10
6 c
ells)
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
Fig. 2
ATO 1μM ̶ + ̶ +
BSO
FLT3
D
B
FLT3-ITD
p-FLT3-ITD
32D /FLT3-ITD
ATO (mM) 0 0.5 1 2
GAPDH
GAPDH
p-FLT3
PARP
C THP-1
ATO (mM) 0 0.5 1 2
FLT3
GAPDH
p-FLT3
ATO (mM) 0 0.5 1 2
MOLM13
FLT3-ITD
Ac-α-Tubulin
HDAC6
GAPDH
A
ATO (mM) 0 0.5 1 2
IP: FLT3
HSP90 IB:
Input
FLT3-ITD
HSP90
E
F
LC3
Actin
FLT3-ITD
ATO 1μM ─ + ─ +
Bor 50 nM ─ ─ + +
p-FLT3-ITD
ATO 1μM ─ + ─ +
MG132 5 μ M ─ ─ + +
FLT3-ITD
Actin
LC3
THP-1
IP: HSP90
HSP90 Input
IB: Ac-Lysine
ATO (mM) 0 0.5 1 2
HSP90 IB:
FLT3-ITD IB:
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
Fig. 3
p-ERK(1/2)
Mcl-1
p-S6
PARP
p-GSK3β
Bcl-2
BimEL
Akt
GAPDH
ATO (mM) 0 0.5 1 2 3 4
A
FLT3-ITD
p-FlT3-ITD
ERK(1/2)
p-Akt
GSK3β
S6
Sor (nM) 0 25 50 100 200
FLT3-ITD
p-GSK3β
PARP
p-S6
Mcl-1
Bcl-2
BimEL
p-ERK1/2
GAPDH
B
p-FlT3-ITD
ERK(1/2)
p-Akt
Akt
GSK3β
S6
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
A
Fig. 4
B
ATO 1 μM
IB:Bak poly
IP: Bak(Ab-1)
Sorafenib 25 nM - - + + IgG
- + - +
ATO 1 μM
IB:Bax poly
IP: Bax(6A7)
Sorafenib 25 nM - - + + IgG
- + - +
D
IB:Bak poly
IP: Bak(Ab-1)
- - + +
- - + +
ATO 1 μM
Sorafenib 25 nM
SB216763 5 μM - + - + IgG
IB:Bax poly
IP: Bax(6A7)
- - + + - - + +
ATO 1 μM
Sorafenib 25 nM
SB216763 5 μM - + - + IgG
E
C
FLT3-ITD
Sor 25 nM ̶ ̶ + +
ATO 1 μM ̶ + ̶ +
PARP
Mcl-1
BimEL
GAPDH
p-GSK3β
Bak
Bax
p-FLT3
GSK3β
0
20
40
60
80
100
0 25 50 100
Sor Concentration (nM)
Ap
op
toti
c ce
lls
(%)
Sor alone
plus ATO 0.5μM
plus ATO 1μM
Bax/Bak
Sorafenib ATO FLT3-ITD
GSK3b
Apoptosis
F
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
B
0
10
20
30
40
50
60
70
80
An
nex
in V
-posi
tive
cell
s (%
)
AML#1
AML#2
AML#3
16.6%
24.5%
29.1%
54.7%
36.2%
66.6%
**
**
**
**
ATO (μM) — 1 — 1 2 2
Sor (μM) — — 5 5 — 5
AML#1 AML#2
FLT3-ITD
Mcl-1
Akt
GAPDH
ATO (μM) 0 1 2 0 1 2
A
Fig. 5 on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Tu
mo
r W
eigh
t (g
)
***
*
##
***
##
** **
ATO (mg/kg) 0 0 2.5 2.5 5 5
Sor (mg/kg) 0 40 0 40 0 40
A B
Treatment No. of mice Survival \Time (d) ILS (%)
Control 5 18.2±1.8 0
ATO 5 21.8±0.8 8.8
Sorafenib 5 35.4±0.9## 94.5
ATO+Sorafenib 5 47.8±1.8## ⃰ 162.6
C
Fig. 6
D a y s
Pe
rc
en
t s
urv
iva
l
0 2 0 4 0 6 0
0
5 0
1 0 0 c o n
A T O
S o r a fe n ib
A T O + S o r a fe n ib
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
Published OnlineFirst June 29, 2018.Mol Cancer Ther Rui Wang, Ying Li, Ping Gong, et al. FLT3-ITD acute myeloid leukemia cellsArsenic trioxide and sorafenib induce synthetic lethality of
Updated version
10.1158/1535-7163.MCT-17-0298doi:
Access the most recent version of this article at:
Material
Supplementary
http://mct.aacrjournals.org/content/suppl/2018/06/29/1535-7163.MCT-17-0298.DC1
Access the most recent supplemental material at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://mct.aacrjournals.org/content/early/2018/06/29/1535-7163.MCT-17-0298To request permission to re-use all or part of this article, use this link
on June 18, 2020. © 2018 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on June 29, 2018; DOI: 10.1158/1535-7163.MCT-17-0298
top related